Profil
Peter Smith is the founder of Remix Therapeutics, Inc., Amplify Medicines, Inc. Dr. Smith is currently an Advisor at Atlas Venture Advisors, Inc. since 2018 and a Member of the Supervisory Board at Ryvu Therapeutics SA since 2023.
Dr. Smith was Chief Scientific Officer at H3 Biomedicine, Inc. from 2011 to 2018.
Dr. Smith earned a doctorate from Newcastle University in 2000 and an undergraduate degree from the University of Sheffield Medical School in 1996.
Postes actifs de Peter Smith
| Sociétés | Poste | Début |
|---|---|---|
| RYVU THERAPEUTICS S.A. | Directeur/Membre du Conseil | 14/06/2023 |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Fondateur | - |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Consultant / Advisor | 01/01/2018 |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Develops pharmaceutical drugs | Fondateur | - |
Anciens postes connus de Peter Smith
| Sociétés | Poste | Fin |
|---|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Corporate Officer/Principal | 31/12/2018 |
Formation de Peter Smith
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Finance |
Newcastle University
Newcastle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Commercial Services |
Ryvu Therapeutics SA
Ryvu Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops and sells therapies for precision oncology | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Develops pharmaceutical drugs | Health Technology |
University of Sheffield Medical School
University of Sheffield Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















